{"id":"NCT02757625","sponsor":"Pfizer","briefTitle":"Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit","officialTitle":"Phase 3, Multi-center, Single-arm, Open-label Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of Da-9501 (Dexmedetomidine Hydrochloride) In Pediatric Subjects In The Intensive Care Unit","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-20","primaryCompletion":"2017-05-24","completion":"2017-05-24","firstPosted":"2016-05-02","resultsPosted":"2018-12-17","lastUpdate":"2018-12-17"},"enrollment":63,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["ICU Sedation"],"interventions":[{"type":"DRUG","name":"Dexmedetomidine hydrochloride","otherNames":[]}],"arms":[{"label":"DA-9501","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy, safety, and pharmacokinetics of dexmedetomidine given as continuous IV infusion in pediatric subjects \\[â‰¥ 45 weeks CGA (corrected gestational age) to \\<17 years old\\] requiring sedation under intensive care unit","primaryOutcome":{"measure":"Percentage of Participants Who Did Not Require a Rescue Sedative Within 24 Hours of Dosing of Study Drug","timeFrame":"From start of study drug administration on Day 1 up to 24 hours of study drug dosing or at the conclusion of mechanical ventilation or the end of study drug administration, whichever is earliest (up to maximum of 28 days)","effectByArm":[{"arm":"Dexmedetomidine: >=45 Weeks CGA to <12 Months","deltaMin":78.6,"sd":null},{"arm":"Dexmedetomidine: >=12 Months to <24 Months","deltaMin":66.7,"sd":null},{"arm":"Dexmedetomidine: >=2 Years to <6 Years","deltaMin":78.9,"sd":null},{"arm":"Dexmedetomidine: >=6 Years to <17 Years","deltaMin":91.7,"sd":null},{"arm":"Dexmedetomidine: All Participants","deltaMin":77.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"45 Weeks","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["Japan"]},"refs":{"pmids":["33813550"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=ZIN-DEX-1506&StudyName=Phase+3%2C+Multi-center%2C+Single-arm%2C+Open-label+Study+Evaluating+The+Efficacy%2C+Safety%2C+And+Pharmacokinetics+Of+Da-9501+%28dexmedetomidine+Hydrochloride%29+In+Pediatric+Subjects+In+The+Intensive+Care+Unit","https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C0801017&StudyName=Phase+3%2C+Multi-center%2C+Single-arm%2C+Open-label+Study+Evaluating+The+Efficacy%2C+Safety%2C+And+Pharmacokinetics+Of+Da-9501+%28dexmedetomidine+Hydrochloride%29+In+Pediatric+Subjects+In+The+Intensive+Care+Unit"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Hypotension","Bradycardia","Respiratory depression","Vomiting","Nausea"]}}